Frontier Biotechnologies Gains NMPA Approval for Albuvirtide Phase II Study
Nanjing-based Frontier Biotechnologies Inc. has announced receiving approval from the National Medical Products Administration (NMPA)...
Frontier Biotechnologies
Frontier Biotechnologies Inc. Gets NMPA Approval for Phase II Study of Albuvirtide as HIV Therapy
Nanjing-based Frontier Biotechnologies Inc. (SHA: 688221) has received approval from the National Medical Products Administration...
Frontier Biotechnologies to Sell 70% of API Unit to Duo Rui Pharma for RMB 10 Million
Nanjing-based Frontier Biotechnologies Inc. is poised to divest a 70% stake in its peptide active...
Nanjing-Based Frontier Biotechnologies Secures Full Approval for Albuvirtide in China
Nanjing-based Frontier Biotechnologies Inc. has announced that its supplementary approval filing for albuvirtide, China’s first...
Frontier Biotechnologies Partners with Yuyue Med for FB2001 Atomizer
China-based Frontier Biotechnologies Inc. (SHA: 688221) announced a strategic collaboration agreement with compatriot firm Jiangsu...
Double-Crane Pharma Gains NMPA Approval for COVID-19 Drug CX2101A Clinical Trials
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving clinical trial approval from...
Frontier Biotechnologies Partners with CASAPC for AIDS Prevention in China
China-based Frontier Biotechnologies Inc. (SHA: 688221) has announced a collaboration agreement with the Chinese Association...
Frontier Biotechnologies Gains CDE Approval for FB2001 COVID-19 Inhalant Study
China-based Frontier Biotechnologies Inc. (SHA: 688221) has announced receiving approval from the Center for Drug...
Frontier Biotechnologies Secures Approval for HIV Therapy Alfusid
Nanjing-based Frontier Biotechnologies Inc. has announced that its supplementary market filing for Alfusid (albuvirtide), China’s...
Frontier Biotech’s FB2001 Inhalant Accepted for NMPA Review
China-based Frontier Biotechnologies Inc. (SHA: 688221) announced that a registrational clinical filing for its FB2001...
Frontier Biotech Partners with Kindstar to Boost Anti-Infection Testing, Especially for HIV
China-based Frontier Biotechnologies Inc. (SHA: 688221) has entered into a partnership with compatriot firm Kindstar...
Frontier Biotech Raises USD 51.4M to Advance COVID-19 Drug FB2001
China-based Frontier Biotechnologies Inc. (SHA: 688221) announced plans to raise RMB 270 million (USD 51.4...
Frontier Biotech and Asymchem Partner on COVID-19 Drug FB2001 Development
China-based Frontier Biotechnologies Inc. (SHE: 200342) announced a strategic partnership with Asymchem Laboratories (Tianjin) Co.,...
Frontier Biotech’s Albuvirtide Shows Promising HIV Treatment Results in Phase III Trial
China-based Frontier Biotechnologies Inc. (SHA: 688221) has released Phase III trial data for albuvirtide, China’s...